Dubois, M. (11 November 2023). Oncolytic Herpes Simplex Virus type 1 armed with CXCL12-antagonist “P2G” to impair glioblastoma stem-like cells self-renewal and migration [Poster presentation]. 15th international oncolytic virus conference, Banff, Canada. |
Dubois, M. (22 December 2022). Oncolytic Herpes Simplex Virus type 1 armed with CXCR4-antagonist “P2G” to disrupt CXCR4/CXCL12 pathway in Glioblastoma [Paper presentation]. 10th ANNUAL BELVIR MEETING, Bruxelles, Belgium. |
Dubois, M. (09 September 2022). Oncolytic HSV-1 armed with P2G to disrupt CXCR4 pathway in Glioblastoma [Paper presentation]. INTERUNIVERSITY PHD STUDENT DAY, Namur, Belgium. |
Dubois, M. (09 September 2022). Oncolytic Herpes Simplex Virus type 1 armed with CXCL12-antagonist “P2G” to disrupt CXCR4/CXCL12 pathway in Glioblastoma [Poster presentation]. INTERUNIVERSITY PHD STUDENT DAY, Namur, Belgium. |
Sanchez Gil, J., Dubois, M., Neirinckx, V., LOMBARD, A., Coppieters't Wallant, N., D'arrigo, P., Isci, D., Aldenhoff, T., Brouwers, B., Lassence, C., ROGISTER, B., Lebrun, M., & Sadzot, C. (2022). Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: a proof-of-principle. Molecular Therapy: Oncolytics. doi:10.1016/j.omto.2022.06.002 |
Dubois, M. (2021). Engineering and characterization of an Oncolytic Herpes Simplex Virus type 1 armed with P2G to disrupt CXCR4 pathway in Glioblastoma Multiforme [Master’s dissertation, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/300323 |
D'arrigo, P., Sanchez Gil, J., Dubois, M., Lebrun, M., ROGISTER, B., & Sadzot, C. (02 August 2021). An armed oncolytic herpesvirus to counteract gioblastoma stem-like cells functions [Poster presentation]. International Herpesvirus Workshop. |